GILD Gilead Sciences Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: GILD

Price (delayed)

$124.87

Market cap

$155.03B

P/E Ratio

16.83

Dividend/share

$3.22

EPS

$7.42

Enterprise value

$169.58B

?
Relative Growth: Rel. Growth: 87
Relative Strength: Rel. Strength: 41
Relative Valuation: Rel. Valuation: 73
Relative Profitability: Rel. Profitability: 98

Gilead Sciences, Inc. /ˈɡɪliəd/, is an American biopharmaceutical company headquartered in Foster City, California that researches, develops and commercializes drugs. The company focuses primarily on antiviral drugs used in the ...

Highlights
GILD's P/E is 79% below its 5-year quarterly average of 82.0 and 11% below its last 4 quarters average of 18.9
GILD's EPS has surged by 56% year-on-year and by 8% since the previous quarter
Sector: Healthcare
Industry: Drug Manufacturers - General
Website: https://www.gilead.com/
Peers: AMGN VRTX ABBV ILMN

Key stats

What are the main financial stats of GILD

GILD stock price

How has the Gilead Sciences stock price performed over time
Intraday
0.9%
1 week
0.46%
1 month
-7.06%
1 year
15.09%
YTD
1.74%
QTD
-10.4%

Financial performance

How have Gilead Sciences's revenue and profit performed over time
Revenue
$29.74B
Gross profit
$23.6B
Operating income
$10.37B
Net income
$9.22B
Gross margin
79.4%
Net margin
31%
The company's net income has surged by 55% YoY and by 8% QoQ
Gilead Sciences's net margin has increased by 49% YoY and by 7% QoQ
The operating income has grown by 26% year-on-year and by 3.5% since the previous quarter
The operating margin has grown by 22% YoY and by 2.6% from the previous quarter

Price vs fundamentals

How does GILD's price correlate with its fundamentals

Growth

What is Gilead Sciences's growth rate over time

Valuation

What is Gilead Sciences stock price valuation
GILD P/E details
P/E
16.83
P/B
6.59
P/S
5.22
EV/EBIT
14.45
EV/EBITDA
11.71
EV/Sales
5.7
GILD's P/E is 79% below its 5-year quarterly average of 82.0 and 11% below its last 4 quarters average of 18.9
GILD's EPS has surged by 56% year-on-year and by 8% since the previous quarter
The stock's price to book (P/B) is 27% more than its 5-year quarterly average of 5.2 but 4.5% less than its last 4 quarters average of 6.9
Gilead Sciences's equity has increased by 23% YoY and by 3.6% from the previous quarter
GILD's price to sales (P/S) is 37% more than its 5-year quarterly average of 3.8 and 2.4% more than its last 4 quarters average of 5.1
GILD's revenue is up by 3.5% year-on-year

Efficiency

How efficient is Gilead Sciences business performance
GILD's return on assets has surged by 50% year-on-year and by 9% since the previous quarter
GILD's return on sales is up by 45% year-on-year and by 8% since the previous quarter
The company's return on equity rose by 33% YoY and by 2.9% QoQ
Gilead Sciences's ROIC has increased by 33% YoY and by 6% from the previous quarter

Dividends

What is GILD's dividend history
Dividend details
DPS
$3.22
Dividend yield
2.58%
Payout ratio
43.4%
Recent dividends

Special dividends are included in TTM DPS and yield

Financial health

How did Gilead Sciences financials performed over time
GILD's total assets is 71% higher than its total liabilities
Gilead Sciences's current ratio has increased by 44% YoY and by 27% QoQ
The quick ratio has grown by 31% YoY and by 24% from the previous quarter
Gilead Sciences's debt is 6% lower than its equity
The company's debt to equity fell by 28% YoY and by 15% QoQ
Gilead Sciences's equity has increased by 23% YoY and by 3.6% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.